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To my mother and father
  
ABSTRACT 
The skin and the mucosal surfaces of humans are colonized with microorganisms 
which are often referred as the normal microflora. There is a biological balance 
between the human host and the normal microflora in health. The extensive use of 
antibiotics in both humans and animals has caused the development of many resistant 
bacteria. Administration of antibacterial agents can cause disturbances in the ecological 
balance between the host and microorganisms.  
Ceftobiprole is a new broad-spectrum cephalosporin active against methicillin-resistant 
Staphylococcus aureus. Twelve healthy volunteers received ceftobiprole. Plasma and 
fecal samples were collected according to the study design for analysis. Plasma 
concentrations of ceftobiprole were 14.7- 24.5 mg/l. No measurable concentrations of 
ceftobiprole were found in feces. There were minor to moderate changes in the 
numbers of enteric bacteria, enterococci, Candida albicans, bifidobacteria, lactobacilli, 
clostridia and Bacteroides spp. No Clostridium difficile strains and no new colonizing 
bacteria were found. 
Ciprofloxacin is a well-known fluoroquinolone active against Gram-negative and 
Gram-positive bacteria. Thirty-six healthy female volunteers according to the study 
design received either the extended release formulation of ciprofloxacin or the 
immediate release formulation. Mean fecal concentrations were 453 mg/kg and 392 
mg/kg, respectively. The numbers of Escherichia coli were significantly suppressed 
while the enterococci decreased moderately in both treatment groups. No toxigenic C. 
difficile strains were found.  
Telavancin is a new glycopeptide for the treatment of Gram-positive infections. 
Thirteen healthy volunteers received telavancin. Fecal and urine samples were collected 
according to the study design. There were no measurable concentrations of telavancin 
in feces. No significant effects on the number of Enterobacteriaceae, enterococci, C. 
albicans, bifidobacteria, lactobacilli, clostridia and Bacteroides spp. were observed in 
the study. No C. difficile strains and no new colonizing Gram positive bacteria were 
found.  
Thirty-four healthy volunteers were included and received either doxycycline or 
placebo for 16 weeks. Plasma, saliva and fecal samples were collected according to the 
study design. The plasma concentrations of doxycycline in the doxycycline group were 
0.20-1.49 mg/l. The fecal concentrations of doxycycline in the doxycycline group were 
0-4.10 mg/kg. Minor effects on the oropharyngeal microflora were observed in both 
groups. There were minor changes in the number of enterococci and E. coli in both 
groups. No C. difficile strains were isolated.  
This thesis shows that intravenous administration of antibiotics (ceftobiprole and 
telavancin) had less impact on the intestinal microflora. Both antibiotics caused minor 
disturbance on the normal microflora indicting a low risk to develop C. difficile 
infection. Ciprofloxacin had impact on the microflora regardless of the formulation of 
the drug. Doxycycline sub-antimicrobial dose had minor effect on the normal 
microflora and development of resistance.  
 
Keywords: Ceftobiprole, Ciprofloxacin, Telavancin, Doxycycline, Oropharyngeal 
microflora, Intestinal microflora, Ecological impact, Normal flora, Health, 
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1 INTRODUCTION 
 
The skin and the mucosal surfaces of human are colonized with microorganisms which 
are often referred to as the normal microflora [1]. There is a biological balance between 
the human host and the normal microflora in health [1]. The normal microflora varies 
between individuals depending on different diet and lifestyle [1]. In an adult 
individual’s intestine there are around 300-500 different species of bacteria, with 30-40 
species comprising up to 99% of the total colonization [1, 2]. Bacteriological studies of 
the fecal microflora show that strict anaerobic bacteria outnumber aerobes by a factor 
of 100 to 1000 [1-4]. The composition of the colonizing microflora influences 
individual variations in immunity against different diseases [5]. 
The most frequent and important cause of instability in the normal microflora is the 
administration of antimicrobial agents [6-12]. To what extent changes of normal 
microflora and instability occur depends on the spectrum, the dose, the route of 
administration, the pharmacokinetic and pharmacodynamic properties of the agent and 
the in vivo inactivation of the antimicrobial agent [6, 7, 9, 11-18]. Antimicrobial agents 
that change and affect the normal microflora also promote the emergence of 
antimicrobial-resistant strains and the risk of super-infection [1, 9-12, 19-21]. 
Antibiotic-resistant organisms have steadily increased for the last 15-20 years, which 
renders threat to present disease management [22, 23]. The resistant bacteria can be 
transmitted to other sites within the host and from individual to individual in the 
hospital environment [24-29]. Inhibition of intestinal flora by antimicrobial drugs 
creates a microbiologic vacuum and these sites may be colonized by antibiotic-resistant 
microorganisms normally excluded [30-35].  Some bacteria of the normal microbiota 
not affected by the antimicrobial agent may also cause overgrowth [6, 8, 11, 18, 33, 35-
37]. If the individual is compromised by surgery, advanced age or immunosuppressive 
therapy, opportunistic bacteria can cause severe infections [10, 11, 18, 38]. Clostridium 
difficile infection (CDI) is one of such infection caused by an opportunistic bacterium 
named C.  difficile [11, 38-40]. The exact mechanism by which C. difficile overgrowth 
occurs is still unclear, but antibiotics are supposed to be the main important risk factor 
for C. difficile infection by reducing the colonization resistance of the intestine 
followed by colonization with C. difficile [11, 38-40]. Antibiotic resistance mechanisms 
exist in both pathogenic bacteria and commensal bacteria surviving the antimicrobial 
attack [37]. Resistance can be inherent, in the genetic composition of that bacterial 
species and can be  acquired also, by which bacteria acquires deoxyribonucleic acid 
(DNA) encoding for resistance or the DNA mutates to become resistant [37].The 
bacteria that are pathogenic and newly established in the gastrointestinal tract are often 
resistant to one or more antimicrobial drugs [11, 37, 38, 41]. Careful investigation of 
the effect of antibiotic treatment on the normal microflora is of importance since 
alteration of the normal flora balance, qualitatively and/or quantitatively, may facilitate 
colonization by new potentially pathogenic strains or enable microorganisms already 
present in the normal flora to develop resistance [3, 6, 7, 9, 10, 20, 38, 42, 43]. 
 
1.1 NORMAL FLORA OF THE OROPHARYNX 
The normal flora of the oropharynx includes a large number of aerobic and anaerobic 
bacterial species [18, 32, 34, 44-47]. Approximately 1x10
9
 bacteria per ml presents in 
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saliva which are mostly anaerobic bacteria. The number of anaerobic bacterium is 10 to 
100 for every aerobic bacterium. Cultureable predominant microorganisms of saliva are 
streptococci, pneumococci, staphylococci, diphtheroids, Haemophilus spp, neisseria, 
micrococci, Peptostreptococcus spp, anaerobic cocci, lactobacilli, Branhamella spp, 
actinomyces, Fusobacterium spp, leptotrichia, Bacteriodes spp, Veillonella spp, 
Prevotella spp, Porphyromonas spp, Candida albicans, various other Gram-negative 
rods, spirochaetes and filamentous forms [35, 44, 46-48]. The normal flora of saliva 
remains relatively constant and is rarely responsible for disease, unless exogenous 
factors such as antibiotic treatment disrupt the balanced flora [18, 34, 35, 45-48]. 
 
1.2 NORMAL FLORA OF THE INTESTINE 
The small intestine is colonized with many different aerobic and anaerobic bacteria 
such as streptococci, enterococci, bifidobacteria, lactobacilli, clostridia, pepto-
streptococci, porphyromonas, prevotella, fusobacteria and bacteroides etc [3, 10, 11, 
34, 46, 47]. The motility of small intestine, p
H
 and the presence of bile are inhibiting 
bacterial multiplication and therefore bacterial concentrations are usually between 1x 
10
2
 to 1x 10
5 
colony forming units per ml small intestinal content [3, 46, 47]. A small 
number of Salmonella and Campylobacter spp can be present asymptomatically in the 
small intestine [3, 46, 47]. 
The normal microflora of large intestine or colon has at least 10
12
 colony-forming unit 
(CFU) per gram feces. More than 500 bacterial species have been identified and 95-
99% of them belong to anaerobic bacteria such as Bacteroides, Bifidobacterium, 
Eubacterium, Peptostreptococcus and Clostridium [3, 46, 47, 49]. In this highly 
anaerobic region of the intestine, these bacteria proliferate and colonize most available 
niches [3, 46, 49]. The strict anaerobic conditions, colonization resistance and bacterial 
waste products are factors that inhibit the growth of other bacteria in the large intestine 
or colon [3, 46, 47, 49]. Enterobacteriaceae, enterococci and C. albicans are 
predominant among aerobic and facultative anaerobic microorganisms [3, 6, 46]. 
Mostly Escherichia coli is dominant from the Enterobacteriaceae group [3, 46, 47, 49].  
 
1.3 SIGNIFICANCE OF THE NORMAL FLORA 
Normal microflora varies and is controlled at different body sites by p
H
, temperature, 
redox potential, oxygen, water, nutrient, peristalsis, lysozyme and immunoglobulins [3, 
5, 32, 46, 47]. Normal microflora influences human anatomy, physiology, lifespan and 
ultimately cause of death [3, 5, 32, 46, 47]. Normally the opportunistic organisms are 
not causing disease but may do so when the host defenses are impaired, such as when 
the normal flora is altered by an antibiotic [3, 32, 46, 47]. Suppressed immune system 
is also a cause of opportunistic bacterial infection [5, 46]. C. difficile, which is an 
opportunistic bacterium, remains viable in a patient undergoing antimicrobial therapy 
and causes CDI [46, 50]. So the infection caused by the normal intestinal flora is 
secondary to another problem [5, 32, 35, 46]. 
Normal microflora in the intestine produces vitamins such as vitamins B12, K, folate, 
riboflavin and helps to break down food that are normally indigestible by the host [5, 
32, 46]. Administration of certain antimicrobial agents causes vitamin K deficiency by 
disrupting normal microflora [51, 52]. Normal microflora and diet play role in the 
development of cancer and obesity [5, 53]. The normal microflora colonizes the 
favorable ecological niches and inhibits colonization of pathogenic bacteria [5, 35, 46, 
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47]. Normal microflora inhibits pathogen organisms multiplication by competing with 
nutrients and production of antibacterial chemicals as a side product of their 
metabolism, thus generating a local antibiotic effect which inhibits the colonization of 
pathogenic microorganisms [3, 5, 32, 46]. Normal microflora helps in the maturation of 
our immune system and keeps it in tune [5, 19, 32, 46]. 
 
1.4 DISTURBANCE OF THE NORMAL MICROFLORA 
Disturbances of the normal microflora in the oropharynx and intestine may be caused 
by antibiotics, malnutrition, contaminated food, contaminated water, surgical 
procedures, emotional stress, environment, food habit, hygiene, age, obesity, immune 
response etc [5, 19, 32, 46]. The most significant and common cause of disturbances in 
the normal oropharyngeal and gastrointestinal microflora is the administration of 
antimicrobial agents [8, 32, 46]. Incomplete absorption of perorally administered agents 
is one of the factors for the disturbances of the microflora [8, 18, 32]. Poorly absorbed 
drugs and antimicrobial agents that are secreted by the salivary glands, in bile and by 
the intestinal mucosa are disrupting the normal microflora [8, 18, 32]. As a 
consequence, this promotes the emergence of resistant microorganisms in 
oropharyngeal and intestinal microflora, as well as dissemination of resistant 
microorganisms [8, 18, 32]. Antimicrobial treatment may lead to a dramatic shift in 
bacterial colonization. [8, 11, 32]. As a consequence, several unwanted effects may 
result, such as overgrowth of already present microorganisms, development of 
resistance, superinfection, colitis etc [8, 11, 32]. Approximately 5% of healthy adults 
asymptomatically carry low numbers of C. difficile in the colon and the growth of these 
bacteria has been shown in vitro to be held in balance by the intestinal normal 
microflora [11, 54, 55]. C. difficile is implicated in 20 to 30% of patients with 
antibiotic-associated diarrhea, in 35 to 50% of those with antibiotic-associated colitis 
and in more than 90% of those with antibiotic-associated pseudomembranous colitis 
[54, 55]. The incidence of CDI ranges from 1 in 100 to 1 in 1,000 hospital discharges 
depending on the antibiotic prescribing habits of the hospital [56]. The incidence may 
change over time at the same hospital as it did in one study from approximately 1 in 
300 to 1 in 100 hospital discharges [56]. Use of antibiotics may lead to the emergence 
of a new variant of C. difficile, which is competent of secreting elevated amounts of 
toxin A and B and is more resistant to the recommended antibiotic treatment [41, 57]. 
This hypervirulent variant, PCR ribotype 027 of C. difficile, has been reported in 
Canada, USA, and Europe [41, 57]. Among all the patients with C. difficile infections, 
recurrence occurs in 15-35% of patients [56, 58]. 
 
1.5 HISTORY OF ANTIBIOTICS 
For a long time the leading cause of death in humans are infections [59, 60]. The main 
causes of death during the 19th century were pneumonia, tuberculosis, diarrhea and 
diphtheria in children and adults [60]. The beginning of industrial revolution and 
upcoming urbanization led to a shift of population to the cities that consequently 
increased the incidence of diseases such as tuberculosis and syphilis [60]. It was 
possible to correlate the existence of microscopic pathogens with the development of 
various diseases in the late 19th century [60]. The antiseptic procedures were 
introduced by Semmelweis and Lister [60, 61]. As a consequence, the mortality due to 
postsurgical infections began to be reduced [60, 61]. A significant role was also played 
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by sanitation and hygiene in the reduction of the mortality due to several infectious 
diseases [60]. In 1911 the first compound with antimicrobial activity was introduced by 
Ehrlich [60, 62-64]. His theory was that the immune system of humans could have been 
aided by the use of chemical compounds [62, 63]. His research activity was focused on 
the discovery of a “magic bullet” to treat syphilis [62-64]. Arsphenamine was the first 
sulfa drug or magic bullet [62-64]. The first compound with antimicrobial activity was 
very successful for controlling many diseases [60, 62-65]. Despite antiseptics and 
magic bullet in hospital and post-surgical, infections induced by Gram-positive bacteria 
remained a common cause of death [60, 62, 65]. The antimicrobial treatment concept 
was revolutionized by Alexander Fleming [66-70]. His curiosity in microbiology and 
antiseptics brought him to the discovery of penicillin, one of the most important drugs 
of the last century [66-70]. Discoveries of more and more new antimicrobials gave 
clinicians more therapeutic options for previously life-threatening diseases [60, 71]. By 
changing the morbidity and mortality, antibiotics have had an effect not only on the 
treatment of infections but also on the society [60, 71]. However, the wide use of 
antimicrobial drugs in humans, animals and agriculture has introduced a new era in 
which clinicians have to face the emergence of drug resistant pathogens [72-78]. The 
condition is provoked by a significant weakening in research and development into 
antibacterial agents [22, 79, 80]. 
 
1.6 ANTIMICROBIAL RESISTANCE 
The leading causes to the emergence and spread of antibiotic resistance include absence 
of regulation in the proper use of antibiotics, transmission of antibiotic resistance genes 
in the community through normal microflora, improper disposal of antibiotics used in 
animals and agriculture [81-90]. Globalization also has an impact on the transmission 
of antibiotic resistance genes in bacteria through immigration and export/import of 
foods [25, 83, 91-93]. Antibiotic resistance is a major problem for the treatment of 
infections and the origin of many antibiotic resistance mechanisms can be traced back 
to environmental organisms [81, 94, 95]. In nature there exists a gene pool for 
resistance to antibiotics for self-defense, homeostasis, detoxification, cell signaling etc 
[94, 95]. There, antibiotics act as weapon, signal and manipulator [81, 94, 95]. The 
spread and maintenance of antibiotic resistant genes are influenced by anthropogenic 
activities [81, 94-96]. Antibiotic resistance genes find their way into the pathogenic 
microorganisms in that way rendering them resilient to most of the antibiotics [81, 94, 
95]. 
Bacteria have the ability to transfer genes from one bacterium to another by lateral gene 
transfer and three steps are required: delivery of the donor DNA into the recipient cell, 
incorporation of the alien genes into the genome of the recipient cell and expression of 
the acquired genes in a manner that benefits the recipient microorganism [91, 94, 97]. 
Delivery of the donor DNA and incorporation of the alien genes into the genome can 
take place by transformation, transduction or conjugation [91, 98]. The resistance 
mechanisms can also be transferred by plasmids [99]. Antimicrobial resistance includes 
three most important mechanisms, i. e. drug target alteration, production of antibiotic-
inactivating enzymes and the cellular membrane barrier preventing drug accessibility (a 
result of decreased influx and increased efflux) [100, 101]. These mechanisms 
frequently interplay synergistically to increase antibiotic resistance levels significantly 
[100, 101]. Antibiotic resistance mechanisms exist in both pathogenic and commensal 
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bacteria surviving the antimicrobial attack [6, 8, 33, 37]. Resistance can be inherent (in 
the genetic composition of that bacterial species), or acquired (bacteria acquires DNA 
encoding for resistance or the DNA mutates to become resistant) [37]. 
The penalties of antimicrobial resistance are longer duration of treatment, higher 
mortality, expensive drugs treatment, costly health system, complex surgeries, 
development of patient as a reservoir of resistant microorganisms for the community 
and health-care personnel and massive impact on the economy [81, 91, 94, 95, 97, 
102]. 
 
1.7 CEFTOBIPROLE  
Ceftobiprole is a novel, broad-spectrum and β-lactamase-stable cephalosporin group 
antibiotic [103, 104]. Ceftobiprole is administered as ceftobiprole medocaril [105]. 
Ceftobiprole medocaril is a water-soluble prodrug for i.v. administration which  is 
rapidly converted to ceftobiprole [105]. Ceftobiprole is primarily eliminated by the 
kidneys as unchanged drug [105]. Methicillin-resistant Staphylococcus aureus (MRSA) 
has emerged in hospitals and in the community [106, 107]. Vancomycin is an effective 
antibiotic against MRSA and wide use of vancomycin has led to the development of 
MRSA isolates with reduced susceptibility [108]. For the treatment of MRSA, 
daptomycin, linezolid, quinupristin– dalfopristin and tigecycline are available on the 
market [108, 109]. MRSA are resistant to most existing β-lactam antibiotics due to their 
production of penicillinase, a low-affinity to penicillin-binding protein (PBP) and 
PBP2a   [110, 111]. Ceftobiprole binds strongly to PBP2a and makes it active against 
MRSA [103, 110, 111]. Ceftobiprole also strongly binds to PBP2x that is liable for β-
lactam resistance in streptococci [103, 111-113]. Moreover, ceftobiprole strongly binds 
to PBP2 and PBP3 in E. coli [103, 111, 112]. It binds to PBP1a-b, PBP2, PBP3, and 
PBP4 in Pseudomonas aeruginosa [111, 112, 114]. It also binds to PBPs in 
Enterococcus faecalis [112, 114]. Ceftobiprole is hydrolyzed by class A 
cephalosporinase, extended-spectrum β-lactamases and carbapenemases [104, 115-
117]. 
 
 
Basic structure of cephalosporin 
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Ceftobiprole medocaril (BAL5788) pro-drug 
 
 
 
Ceftobiprole (BAL9141) active drug 
 
 
Ceftobiprole is active against most aerobic Gram-positive bacteria including MRSA 
and methicillin-susceptible S. aureus (MSSA), vancomycin-resistant E. faecalis and 
Gram-negative bacteria such as Enterobacteriaceae and Pseudomonas spp [110, 117]. It 
is the first cephalosporin to demonstrate clinical efficacy in patients with infections due 
to MRSA [110]. Anaerobic Gram-positive bacteria such as bifidobacteria, 
propionibacteria and peptostreptococci are susceptible while clostridia are variable in 
susceptibility to ceftobiprole. The minimum inhibitory concentration value for C. 
difficile strains is 8.0 mg/l [118]. Bacteroides fragilis and Prevotella species are 
resistant to ceftobiprole [118]. Ceftobiprole has revealed a low potential to select for 
resistance [111]. Ceftobiprole is a promising antimicrobial for monotherapy of 
complicated skin and skin-structure infections (cSSSIs) and pneumonias that have 
required combination therapy in the past [110, 117]. The impact of ceftobiprole on the 
human microflora has not been studied before. 
 
1.8 CIPROFLOXACIN 
Ciprofloxacin is a commonly used fluoroquinolone [119]. It has high bactericidal 
activity against uropathogens [120]. An extended-release formulation of ciprofloxacin 
delivers systemic drug exposure comparable with that achieved with twice-daily 
administration of immediate-release ciprofloxacin [121, 122]. Extended-release 
formulation of ciprofloxacin achieved higher maximum plasma concentrations with 
less inter-patient variability and maintained throughout the 24-hour dosage interval 
[121, 122]. Extended-release formulation of ciprofloxacin is as safe and effective as the 
conventional or immediate-release formulation of ciprofloxacin [121, 122]. It may 
decrease the risk of infection recurrence and occurrence of antimicrobial resistance 
[121]. Since its introduction in the 1980s, the rates of ciprofloxacin resistance have 
remained low [123, 124]. Urinary tract infections (UTIs) are more common in females 
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[119, 125]. Almost 80% of uncomplicated UTIs are caused by E. coli [119, 125]. Other 
microorganisms responsible for UTIs are enterococci, Staphylococcus saprophyticus, 
Klebsiella spp. and Proteus mirabilis [119, 125]. For UTIs in females, the 
recommended first-line treatment is cotrimoxazole and its clinical utility is increasingly 
compromised by the emergence of resistance [119, 126]. Increase of resistance to 
cotrimoxazole has prompted physicians to use ciprofloxacin for UTIs in females [119]. 
 
Ciprofloxacin 
 
For favorable pharmacological profile and high antibacterial activity against clinically 
important Gram-negative and Gram-positive pathogens, ciprofloxacin has become 
widely accepted for the treatment of a wide range of infections including UTIs, 
sexually transmitted infections, skin and bone infections and gastrointestinal infections 
[123, 127]. The impact of ciprofloxacin on the human intestinal microflora has been 
studied before; measurable concentration of ciprofloxacin in feces had been detected [8, 
16, 31]. The aerobic and anaerobic bacteria in the fecal flora were suppressed markedly 
during the prophylactic period as well as during the treatment period [6, 16, 31]. The 
intestinal microflora was almost normal within 2 weeks after treatment [6, 16, 31]. The 
concentrations of ciprofloxacin in the intestinal mucosa and feces were in excess of the 
MICs for most aerobic and anaerobic bacteria [6, 16, 31]. 
 
1.9 TELAVANCIN 
Telavancin is a semisynthetic lipoglycopeptide [128].  Telavancin is invented by 
alkylation of vancomycin to add an extended lipophilic tail [128]. It improved the 
antimicrobial activity and addition of a hydrophilic moiety improved pharmacokinetics 
[128]. Telavancin inhibits bacterial cell-wall synthesis by binding with lipid II and 
inhibiting transglycosylation ten times more than vancomycin [128]. Disruption of the 
functional integrity of the bacterial membrane is another action of telavancin [128, 
129]. Vancomycin does not have this disruption property [128, 129]. Telavancin also 
binds to bacterial membranes, inducing dissipation of membrane potential and 
disruption of bacterial membrane permeability, activities that lead to inhibition of lipid, 
protein, DNA and ribonucleic acid (RNA) synthesis, which results in bacterial cell 
death [128, 129]. Telavancin is primarily eliminated by kidneys without metabolism 
[130].  
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Nosocomial pneumonia is a common infection related with significant mortality [131-
133]. It is the second most common hospital acquired infection [133]. Nosocomial 
pneumonia caused by MRSA is increasing and treatment options for this pathogen are 
limited [133]. The coverage for MRSA is important in the empiric treatment of 
nosocomial pneumonia [134, 135]. Recommending vancomycin or linezolid for 
coverage of MRSA as empiric treatment is not appropriate in all settings, for instance 
in cases of multidrug-resistant strains [134, 135]. As a consequence, there is an urgent 
need for new antimicrobials with activity against MRSA [134-136]. Telavancin should 
be used in known or suspected cases where other alternatives are not suitable [137]. 
Telavancin is approved in the USA and Canada for treatment of cSSSIs and in Europe 
for the treatment of adults with nosocomial pneumonia [137]. Telavancin is active 
against a range of Gram-positive isolates, including MRSA, MSSA, vancomycin-
resistant S. aureus (VRSA), streptococci and vancomycin-susceptible enterococci, but 
it is less active against vanA isolates of vancomycin-resistant enterococci [137-140]. 
Telavancin once-daily dosing makes it a more convenient dosing schedule compared 
with β-lactam antibiotics or vancomycin [141]. The impact of telavancin on the human 
microflora has not been studied before. 
 
1.10 DOXYCYCLINE 
Tetracyclines are an amazing class of antibacterial agents with a lot of therapeutic 
potential [142]. Today the most widely used tetracyclines are minocycline and 
doxycycline [142]. Chlortetracycline discovered in 1945 and tetracycline in 1953 were 
naturally occurring molecules formed by Streptomyces aureofaciens [143] . The 
tetracycline compounds were chemically adjusted to the semi-synthetic doxycycline in 
1967 [143-145]. Tetracyclines are active both against Gram-positive and Gram-
negative bacteria, thus becoming the first class of broad-spectrum antibiotics [142, 
145]. Tetracyclines were found to be highly effective against various pathogens and 
infections including rickettsiae, anthrax, chlamydial infections, community-acquired 
pneumonia, Lyme disease, cholera, syphilis, acute Q fever, Yersinia pestis, 
dermatological diseases, behavior and mental disorders, immune system disorders, 
cardiovascular diseases, nervous system diseases rheumatoid arthritis, corneal 
inflammation, periodontal infections, allergen-induced inflammation and cancer [142, 
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146-148]. Doxycycline may be used in infections with penicillin resistant streptococci 
[146]. 
 
 
Doxycycline, a tetracycline antibiotic 
 
The extensive use of tetracyclines in both humans and animals has caused the 
development of many resistant bacteria and subsequently limited their use in therapy 
[149-151]. Resistance is undoubtedly not limited to the tetracyclines and has been 
reported amongst most classes of antibacterials [150, 151]. Three mechanisms are 
responsible for tetracycline resistance – efflux pump, ribosomal protection and 
chemical modification. Efflux pump and ribosomal protection are the most clinically 
important mechanisms [152-155]. Through the acquisition of tetracycline resistance 
genes, resistance occurs [153-155]. The tet genes are encoded on plasmids, conjugative 
transposons and integrons [150, 151, 153]. 
Tetracyclines have many other interesting properties not related to their antibiotic 
activity [142, 156]. These other interesting properties have led to widely divergent 
experimental and clinical use of tetracycline [156, 157]. Doxycycline has anti-protease 
activities [142, 156, 157]. Doxycycline can inhibit matrix metalloproteinases which 
contribute to tissue destruction activities in diseases such as periodontitis [142, 156, 
157]. Tetracyclines have independent anti-inflammatory effects at sub-antimicrobial 
doses [158-163]. It has immune-modulating and neuroprotective effects [158-163]. 
Studies have provided evidence for the anti-inflammatory properties of tetracyclines, as 
well as in the management of acne and rosacea [158-168]. Traditional tetracycline dose 
has effect on antibiotic susceptibility and resistance of the host microflora [9, 169-172]. 
Subantimicrobial doxycycline dose has raised questions about potential changes in 
antibiotic susceptibility of the host microflora [88]. Many studies have shown that long-
term subantimicrobial doxycycline dose does not contribute to changes in antibiotic 
susceptibility and resistance of the host microflora [173-177]. But studies also reported 
that subantimicrobial dose exposure to microorganisms may select bacteria having 
enhanced multidrug efflux pump activity, which deliver both resistance to 
microorganisms and cross-resistance to multiple antibiotics [88]. It also showed that 
continuous long-term exposure to low level of antibiotics lead to antibiotic resistance in 
pathogenic microorganisms [88]. 
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2 AIMS OF THE THESIS 
 
2.1 PRIMARY OBJECTIVES 
To assess the effect of antibiotic treatment on the intestinal microflora before, during 
and after administration of ceftobiprole (Paper I) or telavancin (Paper III) given to 
healthy volunteers; 
 
To evaluate the ecological impact of the extended release formulation ciprofloxacin in 
comparison with immediate release formulation ciprofloxacin on the intestinal 
microflora in healthy volunteers (Paper III); 
 
To investigate whether a subantimicrobial dose of doxycycline (40 mg) for 16 weeks 
had any ecological impact on the oropharyngeal and intestinal microflora of healthy 
human volunteers (Paper IV).   
 
2.2 SECONDARY OBJECTIVES 
To explore the potential for development of resistance by measuring the MICs of new 
colonizing isolated bacterial strains during and after antibiotic administration (Paper I, 
II, III and IV); 
 
To correlate the intestinal and oropharyngeal microflora patterns with drug 
concentrations measured in feces (Paper I, II, III and IV), saliva (Paper IV) and plasma 
(Paper I); 
   
To determine the pharmacokinetics of telavancin in plasma and urine (Paper III); 
 
To assess the safety of the drug (Paper I, II, III and IV). 
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3 MATERIALS AND METHODS 
 
3.1 SUBJECTS 
3.1.1 Paper I 
This was an open-label, non-comparative, multiple-dose, single-center study. Twelve 
healthy volunteers (6 males and 6 females) aged between 20 and 31 years were 
included in the study. They were recruited through information and advertisement 
about the study on the Clinical Pharmacology Trial Unit website 
(http://www.karolinska.se/KarolinskaUniversitetslaboratoriet/Kliniker/Klinisk-
farmakologi/Humanlaboratoriet/) of the Karolinska University Hospital, Stockholm, 
Sweden.  
 
3.1.2 Paper II 
This was a randomized, two-armed, parallel study. Thirty-six healthy female volunteers 
aged between 18 and 45 years were included in the study. Half of the volunteers were 
18-35 years and another half of the volunteers were 36-45 years. Trial Form Support 
(TFS), Lund, Sweden, recruited all the volunteers through advertisement. 
 
3.1.3 Paper III 
This was an open-label, single-dose, single-center study. Thirteen healthy volunteers (6 
males and 7 females) aged between 18 and 40 years were included in the study. All the 
volunteers were admitted to the clinical research unit (PRA International, Zuidlaren, 
The Netherlands) by advertisement. 
 
3.1.4 Paper IV 
This was a double blind, randomized, placebo-controlled, parallel group study. Thirty- 
four healthy volunteers (16 males and 18 females) aged between 19 and 37 years were 
included in the study. The volunteers were recruited through information and 
advertisement about the study on the Clinical Pharmacology Trial Unit website of the 
Karolinska University Hospital, Stockholm, Sweden. 
 
3.2 INCLUSION CRITERIA 
Necessary physical examinations were carried out on each volunteer at the screening 
visit, including measurements of blood pressure, heart rate, electrocardiogram (ECG) 
and clinical laboratory safety tests as well as an interview on medical and surgical 
history. Female volunteers were tested for pregnancy. Included volunteers had to 
adhere to the visit schedule and concomitant therapy prohibitions and be compliant 
with the treatment. Volunteers aged between 18 and 45 years with regular defecation 
(five or more per week) and normal findings in the medical history and physical 
examination were included in the studies. Body weights were 60.0–100.0 kg for male 
subjects and 50.0–90.0 kg for female volunteers, with a body mass index between 18.0 
kg/m2 and 26.0 kg/m2 both for male and female volunteers. Female volunteers of 
childbearing potential were required to use a highly effective and approved 
contraceptive method during the entire study period and 3 months after completion of 
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the studies. During this period, other antibiotic treatment was prohibited.  In paper II 
the healthy volunteers were females and in the papers I, III and IV both males and 
females were included. 
 
3.3 EXCLUSION CRITERIA 
Volunteers were not eligible if any of the following criteria was met: Regular use of 
medication (except contraceptive tablets); treatment with antimicrobial agents  or 
participation in a trial with another investigational drug within the 3 months preceding 
inclusion in the study; presence of any gastrointestinal disease 1 month preceding the 
study; use of probiotic products; presence of any surgical or medical condition that 
might interfere with the absorption, distribution, metabolism or excretion of drugs; 
known case of CDI,  central nervous system (CNS) disorder, abnormal blood pressure 
(above 140 mmHg systolic and/or above 90 mmHg diastolic; below 100 mmHg 
systolic and/or below 60 mmHg diastolic), abnormal heart rate (above 110 beats/min 
and/or below 50 beats/min), decreased creatinine clearance (<80 mL/min), positive 
screen for hepatitis B or C or human immunodeficiency virus (HIV) and alcohol or 
substance abuse disorder; pregnant, breast-feeding or having the intention of becoming 
pregnant or not using acceptable contraceptive measures; donation of blood or blood 
products within 1 month prior the study; medical or physical findings considered to be 
clinically significant; volunteers suffering from constipation; history of hypersensitivity 
to β-lactam antibiotics (paper I); history of hypersensitivity to quinolones or history of 
tendon disorders related to quinolones administration (paper II); known or suspected 
hypersensitivity to telavancin (paper III); known or suspected hypersensitivity to 
tetracycline (paper IV) or to any components of the formulation used; hypersensitivity 
to the excipients and concomitant direct exposure to either extensive sunlight or 
ultraviolet (UV) irradiation; recent  travel history to tropical countries (within last 3 
months); deviating renal function; decreased amount of thrombocytes; any clinically 
significant abnormality following the investigator's review of the pre-study physical 
examination,  ECG and clinical laboratory tests; or any other clinical conditions that in 
the opinion of the responsible physician would not allow safe completion of the study. 
 
3.4 INFORMED CONSENT 
According to the inclusion/exclusion criteria, the volunteers were informed about the 
study both verbally and by written information. The volunteers had enough time to 
consider participation and opportunity to ask the physician. When a volunteer 
participated, she/he signed a consent form, after which study activities had been 
performed. The volunteer was also given a copy of the signed consent form.  
 
3.5 STUDY DESIGN 
3.5.1 Paper I 
The volunteers were admitted to the study center the day before the first drug 
administration and discharged from the study center on Day 8. Each volunteer included 
in the study participated at follow-up visits on Days 10, 14 and 21.  
From each volunteer, 13 plasma samples were collected as followed: one at pre-dose 
(Day −1), 3 samples each on Days 1, 4 and 7 and 1 sample each on Days 10, 14 and 21. 
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From each volunteer, 7 fecal samples were collected at pre-dose (Day −1) and on Days 
2, 4, 7, 10, 14 and 21.  
 
3.5.2 Paper II 
Each volunteer passed inclusion criteria was allocated to one of the following 
treatments groups, the extended release formulation ciprofloxacin treatment (ERT) or 
the immediate release formulation ciprofloxacin treatment (IRT), according to a 
computer-generated randomization code list prepared by the TFS, Lund, Sweden. The 
treatment randomization was stratified by age. The study treatment was not blinded for 
the volunteers and the clinical staff. Intestinal microflora assessments were blinded. 
First fecal samples were collected for the study on the screening day. The study drug 
for the whole treatment period was dispensed to the volunteers. The volunteers were 
informed about how to take the antibiotics and how to proceed if one dose was 
forgotten. Feces collection tubes were handed out together with information on how 
and when to carry out samplings. Included volunteers visited the site 4 times during the 
study: Visit 1 screening/including randomization/start of treatment; Visit 2, end of 
treatment; Visit 3, 7 days after the end of treatment; Visit 4, 2 weeks after the end of 
treatment. 
 
3.5.3 Paper III 
Volunteers were admitted to the clinical research unit the day before the first dose of 
antibiotic administration and discharged from the clinical research unit on Day 9. 
Volunteers visited the clinical trial center on Days 10, 14 and 21 for follow up.  
For microbiological analysis and for bioassay of telavancin, seven feces samples were 
collected: at pre-dose (Day −1) and on Days 2, 5, 7, 9, 14 and 21. Plasma samples were 
collected to evaluate the pharmacokinetics of telavancin on Day -1 (pre-dose), on Days 
5, 6 and 7. For pharmacokinetics analysis additional plasma samples were taken on Day 
7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 h after start of infusion. Urine was 
collected over 24 h after the last dose to determine the excretion of telavancin. 
 
3.5.4 Paper IV 
Volunteers visited the clinical trial center six times as followed screening day, Day -1 
(pre-administration) and at Weeks 4, 8, 16 and 20. 
For pharmacokinetics analysis from each volunteer, five plasma samples were collected 
at baseline visit (2 h after the oral dosing) and at Weeks 4, 8, 16 and 20. Saliva and 
feces samples were collected on Day -1 and at 4, 8, 16 and 20 weeks post dosing for 
pharmacokinetic and microbiological analyses. 
 
3.6 ETHICS COMMITTEE’S APPROVAL  
The study protocols were submitted to the Ethics Committee of Karolinska Institutet, 
Stockholm, Sweden (Paper I and IV), the Medical Products Agency, Uppsala, Sweden 
(Paper I, II and IV), the Ethics Committee of the Lund University, Lund, Sweden 
(Paper II) and were approved before the trials were started. The study protocol for 
paper III was submitted to the local ethics committee by the clinical research unit of 
PRA International, Zuidlaren, The Netherlands and approved before the clinical trial 
was started. 
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3.7 DRUG ADMINISTRATION 
3.7.1 Ceftobiprole 
By intravenous infusion, 500 mg of ceftobiprole was given to each volunteer over 120 
minutes every 8 h (q8h) for 7 days. 
 
3.7.2 Ciprofloxacin 
Extended release formulation ciprofloxacin (Utiminx
®
 500 mg, Rottapharm Madaus 
SpA, Monza, Italy) was taken once daily together with a meal for 3 days.  The 
comparator immediate release formulation ciprofloxacin (Ciproxin
®
 250 mg, Bayer 
HealthCare AG, Leverkusen, Germany) was taken twice daily for 3 days. The tablets 
were swallowed whole with fluid, not cut, crushed or chewed. The first dose was 
administered after the first feces sampling. 
 
3.7.3 Telavancin 
By intravenous infusion of 10 mg/kg body weight, telavancin was given over a 60-min 
period once every 24 h for 7 days. 
 
3.7.4 Doxycycline  
Orally, 17 volunteers were given Doxycycline 40 mg capsules (Efracea
®
; Galderma, 
Sophia Antipolis, France) and 17 volunteers received placebo 40 mg capsules 
(Galderma) for 16 weeks, once daily. 
 
3.8 TREATMENT COMPLIANCE  
The medications were supervised to ensure treatment compliance by the responsible 
persons or staffs of clinical research or trial unit. Staffs performed drug accountability 
and recorded the relevant information in the case report form (CRF). 
 
3.9 SAMPLING PROCEDURE 
3.9.1 Feces  
Samples from feces were collected according to the study design in conjunction with 
each visit, either at the volunteer’s home or at the clinical trial unit during the study 
period in a sterile container and were recorded with the study number, volunteer 
number and date and time of collection. The collection containers were filled up to the 
top. If the feces sample was collected at home, it was kept at +4
°
C or at -20
°
C until it 
was brought to the site of the clinical trial unit. In the CRF the time of collections was 
also recorded. The first specimen collected was analyzed if more than one feces 
specimen were collected on a given day for pharmacokinetic and microbiological 
analyses. If none was passed on a given day, the first specimen passed after that day 
was collected for analyses.  
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3.9.2 Blood 
Samples from blood for evaluation of pharmacokinetics (Paper I, III and IV) and for 
bioassay (Paper I) were collected into sterile blood collection tubes, containing 
sodium–heparin as anticoagulant according to the respective study design and were 
labeled appropriately with the study number, volunteer number, date and time of 
collection. Collected blood samples were immediately put on ice and were centrifuged 
within 30 minutes at 1500 × g for 10 min at 4
°
C to obtain plasma. 
 
3.9.3 Saliva 
Saliva (Paper IV) was collected in a sterile container and labeled with the study 
number, volunteer number, date and time of collection. Samples were collected 
according to the study design for pharmacokinetic, microbiological analyses and 
bioassay. 
 
3.9.4 Urine 
Samples from urine (Paper I, II, III and IV) were collected at the site of clinical trial 
unit and pregnancy tests were completed by the clinical staff. For bioanalysis of 
telavancin (Paper III), urine was collected and labeled appropriately. In all containers 3-
[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) was added to 
prevent adsorption of telavancin by the container wall. The sample was inverted gently 
several times to thoroughly mix the contents and divided into three aliquots at the end 
of each interval. Aliquots were labeled with the study number, volunteer number, date 
and time of collection. 
 
3.9.5 Storage and transportation  
At site of clinical trial unit all samples (Paper II and III) were frozen immediately in a -
70°C freezer and time was recorded in the CRF. According to the study design, 
relevant samples were shipped with adequate dry ice to the Division of Clinical 
Microbiology, Department of Laboratory Medicine, Karolinska University Hospital, 
Stockholm, Sweden, for microbiological analysis and bioassay. Feces and plasma 
samples (Paper I and IV) were transported to the Division of Clinical Microbiology, 
Department of Laboratory Medicine, Karolinska University Hospital, within 30 min of 
collection time and were stored at −70°C until processed. 
 
3.10 DETERMINATION OF ANTIBIOTIC CONCENTRATION IN FECES, 
PLASMA, SALIVA AND URINE 
3.10.1 Antibiotic concentration in feces by bioassay (Paper I, II, III and 
IV) 
Fecal concentrations of ceftobiprole (Paper I), ciprofloxacin (Paper II), telavancin 
(Paper III) and doxycycline (Paper IV) were assayed by the agar well (4 mm in 
diameter) diffusion method. The agar plates were made by antibiotic medium No. 1 
(Paper I, II and III) (Difco, Sparks, MD, USA) or nutrient broth (Paper IV) (BBL, 
Cockeysville, MD, USA) and agarose (Sigma, St Louis, MO, USA) with p
H
 8, on Nunc 
bioassay plates 24 cm × 24 cm (Thermo Fisher Scientific, Waltham, MA, USA).  
Micrococcus luteus ATCC 9341 (Paper I and III), E. coli ATCC 25922 (Paper II) and 
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Bacillus cereus ATCC 11778 (Paper IV) were used as the indicator strains. The 
respective indicator strain was suspended in 0.9% NaCl with a density of 10
7
 CFU/ml 
and the agar surface was inoculated by the suspension [178, 179]. Samples were always 
analyzed in duplicate and put in randomized order. Fecal samples were first diluted 1:4 
(w/v) in 0.1 M NaOH (p
H
 8). Samples were homogenized thoroughly by vortex and 
then centrifuged at 5000 rpm for 12 min. The supernatants were diluted in 0.15 M 
phosphate buffer (p
H
 8) according to the need. The standards of ceftobiprole, 
ciprofloxacin, telavancin and doxycycline according to the companies' provided 
instructions. Inhibition zones were measured after incubation for 18 h at 37
°
C and 
standard curves were used to calculate the concentration. The standard curves were 
based on a logarithmic regression model and the correlation coefficients of the standard 
curves were 0.99 for all plates. For the final calculation of antibiotic measurement 
mean values from the duplicates were taken. The lower limit of sensitivity was 0.25 to 
1 mg/kg feces, 
 
3.10.2 Antibiotic concentration in plasma (Paper I) and saliva (Paper IV) 
by bioassay 
In the plasma or saliva, concentrations were determined on antibiotic medium no. 1 
(Difco) with Micrococcus luteus ATCC 9341 (Paper I) or Bacillus cereus ATCC 11778 
(Paper IV) as indicator strain [178, 180]. The standards of ceftobiprole were prepared 
in human serum in the range 0.25–64 mg/l and plasma samples were also diluted in 
healthy human serum according to the need. The normal human serum used here was 
collected from the Transfusion Medicine Department of Karolinska University Hospital 
that was collected from healthy humans with no history of antibiotic exposure in 3 
months. The determination of the drug concentration in plasma followed the same 
protocol as for the feces described above.  
 
3.10.3 Ceftobiprole (Paper I) plasma and fecal concentrations by high-
performance liquid chromatography (HPLC)  
Ceftobiprole plasma and feces concentrations were determined by the following 
developed and validated methods. An ultra-performance liquid chromatography–
tandem mass spectrometry (UPLC–MS/MS) system (Waters Corp., Milford, MA, 
USA) was used for determining the ceftobiprole in lithium (Li) heparin human plasma 
(p
H
 8). Samples were prepared by protein precipitation with 1% formic acid in 
acetonitrile containing BAL0009141-d4 as an internal standard. Into the UPLC–
MS/MS system the final extract of plasma samples was injected.  
In the same way as plasma, concentrations of ceftobiprole in fecal extract (supernatant 
from human fecal acidic homogenized with phosphate-buffered saline solution) were 
determined. 
An ACQUITY UPLC BEH C18 column (1.7 μm, 2.1 × 50 mm) (Waters Corp.) using a 
gradient run with mobile phase A of 0.1% formic acid in water and mobile phase B of 
acetonitrile separation of analytes was used. By using a Micromass Quattro Premier XE 
mass spectrometer (Waters Corp.) operating in positive electrospray ionization mode 
utilizing multiple reaction monitoring for the transitions 535 → 203 m/z for 
ceftobiprole and 539 → 207 m/z for IS (International System of Units) analytes were 
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detected. The calibration curve in plasma was linear over the range 0.05–30 mg/l 
plasma and in fecal extract over the range 1.00–143 mg/kg feces.  
 
3.10.4 Doxycycline plasma concentrations by HPLC (Paper IV) 
Samples from plasma were assayed for doxycycline using a validated liquid 
chromatography tandem mass spectrometry (LC–MS/MS) method. The quantification 
limit was 15 ng/ml plasma. 
 
3.10.5 Antibiotic concentration in saliva by bioassay (Paper IV) 
Doxycycline concentrations in saliva samples were determined in the same way as the 
feces concentration was measured and the indicator strain was B. cereus ATCC 11778 
[178-181].  
 
3.10.6 Telavancin concentrations in plasma and urine by HPLC (Paper 
III) 
Plasma or urine samples (50 μl) spiked with the internal standard (deuterated 
telavancin) were acidified and loaded into Strata-X-C (3 mg) 96-well plates 
(Phenomenex Inc., Torrance, CA, USA) and were washed with 0.1 M HCl and then 
with methanol. Methanol elution was performed with ammonium hydroxide. Before 
being injected in a LC–MS/MS system (Sciex, Foster City, CA, USA), elute was 
evaporated to dryness and was reconstituted again. 
From the matrix telavancin was separated by liquid chromatography and was detected 
by mass spectrometry. Using a gradient mobile phase, chromatographic separation was 
carried out in an Agilent 1200 SL G1312B LC system equipped with a Hypersil Gold 
column (2.1 mm I.D. × 150 mm length, 5 μm) (Agilent Technologies Inc., Santa Clara, 
CA, USA). Mobile phase A consisted of 1% formic acid/5% methanol in water. Mobile 
phase B was 1% formic acid/20% water in acetonitrile. With an increasing 
concentration of phase B, the separation was performed. The flow rate was 400 μl/min. 
API 4000 triple quadrupole mass spectrometer (Sciex) equipped with an electrospray 
interface operated in multiple reaction monitoring (MRM) positive ion mode was used 
for the quantification of telavancind. The temperature in the source was 550°C, ion 
spray voltage 5.2 kV and the dwell time 75 ms. The following transitions were selected 
for MRM: 586.2 > 112.2 for telavancin and 593.2 > 112.2 for the internal standard. 
Analyst
®
 software (Sciex) was used for the data acquisition and analysis. 
For plasma, the limit of quantification of the method was 0.10 μg/ml and 0.25 μg/ml for 
urine. For plasma, the response of telavancin was linear in the range 0.10–25.0 μg/ml 
and for urine 0.25–80.0 μg/ml. With accuracy and precision better than 15%, the 
coefficient of variation was always >0.99 
 
3.11 ESTIMATION OF TELAVANCIN PHARMACOKINETIC PARAMETERS 
Telavancin pharmacokinetic parameters were calculated by non-compartmental 
analysis using WinNonlin
®
 Professional software v.5.3 (Pharsight Corp., Sunnyvale, 
CA, USA). The calculated parameters were: the amount of unchanged excreted drug in 
urine over a dosing interval, percentage of the dose excreted unchanged in urine, 
AUCtau, Cmax in plasma; trough Cmin in plasma total body total body clearance (CL), 
renal clearance (CLR); time to maximum drug concentration in plasma (Cmax); terminal 
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elimination of half-life (t1/2), volume of distribution in steady state (Vdss) and volume of 
distribution based on terminal phase (Vz). 
 
3.12 PROCESSING OF SPECIMENS FOR MICROBIOLOGICAL ANALYSES 
Samples from feces (Paper I, II, III and IV) and saliva (Paper IV) were suspended in 
pre-reduced peptone yeast extract medium, diluted ten-fold and inoculated on non-
selective and selective agars as described by Nord et al. [181]. Aerobic agar plates were 
incubated for 24 h at 37
°
C and anaerobic plates for 48 h at 37
°
C in anaerobic jars 
(GasPak™; BBL, Cockeysville, MD, USA). Following incubation, different colony 
types were counted and isolated in pure culture.  All isolates were identified according 
to Gram-reaction and colony morphology, followed by biochemical tests to genus level 
[46]. The anaerobic microorganisms were identified by gas chromatographic analysis 
[46, 182]. C. difficile strains were further characterized by the cell cytotoxicity 
neutralization assay, PCR ribotyping and a multiplex real-time polymerase chain 
reaction (PCR) (Xpert
®
 C. difficile Assay; Cepheid, San Francisco, CA, USA) as 
recently described [183]. The lower limit of detection for microorganisms was 10
2
 
CFU/g feces or 10
2
 CFU/ml saliva. 
 
3.13 ANTIBIOTIC SUSCEPTIBILITY TESTS 
The minimum inhibitory concentrations (MICs) of ceftobiprole (Paper I), ciprofloxacin 
(Paper II), telavancin (Paper III) and doxycycline (Paper IV) were determined for 
isolated strains from agar plates containing antibiotic. Using the agar dilution method, 
MICs were determined for strains isolated from ceftobiprole (4 mg/l) agar plates;  
ciprofloxacin (1mg/l) agar plates; telavancin  (2 mg/l) agar plates; or doxycycline  (4 
mg/l) agar plates [184-186]. The final inoculum was 10
4
 CFU/spot for aerobic bacteria 
and 10
5
 CFU/spot for anaerobic bacteria. Inoculated plates were incubated for 24 h 
(aerobic bacteria) and 48 h (anaerobic bacteria). Reference strains were E. coli ATCC 
25922, S. aureus ATCC 29213, E. faecalis ATCC 29212, B.  fragilis ATCC 25285 and 
C. difficile ATCC 700057. The strains were considered resistant according to 
breakpoints used in clinical and laboratory standards institute (CLSI) recommendations 
(Paper I, III and IV) or according to break-off points used in the European committee 
on antimicrobial susceptibility testing  (EUCAST) guidelines (Paper II) [184-186]. The 
MIC was defined as the lowest concentration of drug that inhibited growth completely. 
MIC50 and MIC90 values corresponded to the concentrations that inhibited the growth of 
50% and 90% of the strains tested, respectively. All antimicrobial agents were 
dissolved and diluted according to the companies’ instructions. 
 
3.14 SAFETY AND ADVERSE EVENTS 
A safety assessment was conducted for all volunteers at baseline and at every following 
visit. Safety parameters were the adverse events (AEs). A physical examination was 
performed at each study visit. An adverse event was any event that impaired the 
wellbeing of a subject during the period of observation in the clinical study, including 
illness or accident. Other safety variables were: abnormalities at physical examination, 
vital signs and concomitant medications. Abnormalities that did not constitute an 
exclusion criterion and that were judged as not clinically significant were also recorded. 
Systolic and diastolic blood pressure and heart rate were measured at all visits. 
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The investigator was responsible for the necessary acute medical treatment of any 
adverse event during the trial and ensured that appropriate medical care was maintained 
thereafter. All findings were reported on an ‘adverse event’ page in the case report form 
and in the subject's medical records. AE incidences were summarized for all AEs and 
for related AEs by system organ class (SOC) and preferred time (PT) based on the 
medical dictionary for regulatory activities (MedDRA) dictionary (version 13.0). 
 
3.15 STATISTICAL METHODS 
Results were calculated for the values estimated for saliva and feces samples as log 
number of microorganisms per ml of saliva or per gram of feces. Feces, saliva and 
plasma concentrations done by bioassays were calculated from standard curves. For the 
pharmacokinetic analyses fecal, plasma and urine concentrations calculations were 
done by the Wilcoxon signed-rank test and Mann-Whitney U-test. IBM SPSS Statistics 
20 (Armonk, NY, USA) software was used to calculate the percentiles 50 and 90 of the 
MIC results. In general, descriptive statistics were used to summarize both the 
microbiological and pharmacokinetic data. 
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4 RESULTS 
 
4.1 EFFECT OF CEFTOBIPROLE ON THE NORMAL HUMAN 
INTESTINAL MICROFLORA (PAPER I) 
4.1.1 Ceftobiprole concentrations in plasma and feces 
All the volunteers (6 males and 6 females) finished the study successfully. Plasma 
ceftobiprole concentrations are shown in Table 1. Concentrations in samples taken 10 
min after completion of infusion were as follows: Day 1, 14.7–23.6 mg/l (mean 19.4 
mg/l); Day 4, 15.9–24.5 mg/l (mean 20.5 mg/L); and Day 7, 15.9–23.9 mg/l (mean 20.3 
mg/l). No ceftobiprole was detected in plasma on Days −1, 10, 14 and 21. No 
measurable fecal concentrations were found on Days −1, 2, 4, 7, 10, 14 and 21. 
 
 Time (Days) 
Subject 
No. 
-1 2 4 7 10 14 21 
1 ND 19.5 22.0 18.0 ND ND ND 
2 ND 14.7 17.3 15.9 ND ND ND 
3 ND 20.4 23.1 20.7 ND ND ND 
4 ND 15.6 21.8 20.8 ND ND ND 
5 ND 22.9 23.1 21.9 ND ND ND 
6 ND 15.3 16.9 20.1 ND ND ND 
7 ND 20.9 18.7 19.9 ND ND ND 
8 ND 22.5 21.3 21.7 ND ND ND 
9 ND 21.4 22.7 21.9 ND ND ND 
10 ND 18.1 15.9 18.6 ND ND ND 
11 ND 23.6 24.5 23.9 ND ND ND 
12 ND 18.1 18.5 19.7 ND ND ND 
Range - 14.7-23.6 15.9-24.5 15.9-23.9 - - - 
Mean - 19.4 20.5 20.3 - - - 
ND – Not detected 
 
Table 1. Ceftobiprole plasma concentrations 10 min after completion of infusion in 12 
volunteers receiving 500 mg doses of ceftobiprole intravenously every 8 h for 7 days. 
 
4.1.2 Effect of ceftobiprole on the aerobic intestinal microflora 
The effect of ceftobiprole on the aerobic intestinal microflora is shown in Figure 1. 
Mean counts of E. coli decreased by ca. 1.5 log CFU/g of feces from study Day −1 to 
study Day 7, with recovery to baseline counts on Day 21. Mean values for 
Enterobacteriaceae did not change from study Day −1 to study Day 21. Mean numbers 
of enterococci decreased 1.0 log CFU/g of feces from Day −1 to Day 7 and then 
increased 2 log CFU/g of feces to Day 14; on Day 21 the numbers of enterococci were 
recovered to baseline. The numbers of Candida albicans were within the normal 
variation. Changes in the aerobic intestinal microflora (≤2 log CFU/g of feces) were not 
significant. 
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Figure 1. Effect of ceftobiprole administration on the aerobic intestinal microflora of 12 
healthy volunteers. Solid line represents mean value of logarithmic number of 
microorganisms/g of feces. 
 
4.1.3 Effect of ceftobiprole on the anaerobic intestinal microflora 
The effect of ceftobiprole on the anaerobic intestinal microflora is shown in Figure 2. 
There were no changes in the numbers of lactobacilli and bifidobacteria from Day −1 to 
Day 21. Counts of clostridia increased from Day 2 to Day 7 by 1.5 log CFU/g of feces 
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and then returned to baseline counts. The numbers of Bacteroides were only influenced 
on Day 2, with a decrease of 0.5 log CFU/g of feces. All alterations were within the 
normal variation. No C. difficile strains were found. 
 
 
Figure 2. Effect of ceftobiprole administration on the anaerobic intestinal microflora of 
12 healthy volunteers. Solid line represents mean value of logarithmic number of 
bacteria/g of feces. 
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4.1.4 Ceftobiprole susceptibility tests 
No new colonizing aerobic and anaerobic bacteria resistant to ceftobiprole (MIC ≥ 4 
mg/l) were found. 
 
4.1.5 Safety and tolerability 
There were 10 volunteers with 28 adverse events, all mild in severity. Four events of 
common cold, one event of very mild swelling of the lower lip, one event of vasovagal 
reaction in relation to i.v. cannula insertion and one event of muscle pain were 
considered to be unrelated to the study drug. Other adverse events were considered to 
be possibly related to ceftobiprole and included infusion-site reactions in three 
volunteers, with pain, mild swelling and thrombophlebitis in one volunteer. Mild rash 
was seen in three volunteers and vaginal candida infection in two volunteers. Two 
volunteers had two events of headache each. One volunteer had two events of mild 
diarrhea. Nausea was seen in one volunteer. During study drug infusion, five volunteers 
noticed mild taste alterations. No volunteer had potentially clinically significant 
changes in post-baseline vital sign values. No volunteers had potentially clinically 
significant changes in post-baseline hematology, chemistry or urine analysis based both 
on normal ranges and on percent change from baseline. There were no significant 
changes in ECG parameters from baseline to post baseline in any volunteer. 
 
4.2 COMPARATIVE EFFECTS OF THE IMMEDIATE AND THE EXTENDED 
RELEASE FORMULATIONS OF CIPROFLOXACIN ON THE 
INTESTINAL MICROFLORA (PAPER II) 
4.2.1 Eligible and non-eligible volunteers 
For the study, 36 volunteers were screened and randomized. Eighteen volunteers 
received extended release formulation ciprofloxacin and 18 volunteers received 
immediate release formulation ciprofloxacin. In the extended release formulation 
ciprofloxacin group, one volunteer provided limited fecal material and two volunteers 
had non-conclusive ciprofloxacin concentrations in feces. All three volunteers were 
therefore excluded. In the immediate release formulation ciprofloxacin group, one 
volunteer provided limited fecal material, three volunteers had non-conclusive 
ciprofloxacin concentrations and one volunteer deviated from the protocol. All five 
volunteers were therefore excluded.  
 
4.2.2 Ciprofloxacin concentrations in feces 
The volunteers receiving the extended release formulation ciprofloxacin (Volunteers 
number 1, 2, 6, 9, 10, 12, 14, 16, 17, 27, 28, 29, 35, 37, 41) had mean concentration of 
ciprofloxacin 453 mg/kg on visit 2, the median concentration of ciprofloxacin was 432 
mg/kg and the standard deviation was 164 mg/kg.  
In the immediate release formulation ciprofloxacin group volunteers (Volunteers 
number 3, 5, 7, 8, 11, 13, 15, 18, 30, 32, 33, 40, 42) the mean concentration of 
ciprofloxacin on visit 2 was 392 mg/kg, the median concentration of ciprofloxacin was 
304 mg/kg and the standard deviation was 231 mg/kg. The mean and median 
concentrations of ciprofloxacin in the feces were 61 mg/kg and 128 mg/kg higher in the 
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extended release formulation group as compared to the immediate release formulation 
group. No ciprofloxacin was detected in feces on visits 1, 3 and 4 in both groups. 
 
4.2.3 Effect of ciprofloxacin agents on the intestinal aerobic and 
anaerobic microflora 
The impact of the extended release formulation ciprofloxacin on the numbers of E. coli, 
Enterobacteriaceae, enterococci and B. fragilis in the intestinal microflora is shown in 
Figure 3 (Filled circles and dotted line). The numbers of E. coli were significantly 
suppressed while the enterococci decreased moderately.  
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Figure 3. Effect of the extended release formulation (Filled circles and mean dotted 
line) ciprofloxacin and the immediate release formulation (Empty circles and mean 
solid line) ciprofloxacin administration on the intestinal microflora.  
 
No significant effects were observed on the Enterobacteriaceae (Klebsiella and 
Enterobacter species) and B.  fragilis. No C. difficile strains or toxins were detected in 
the extended release treatment group. The fecal flora was normalized 2 weeks after end 
of treatment. 
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In the volunteers receiving the immediate release formulation ciprofloxacin, similar 
findings were observed in the intestinal microflora (Figure 3 Empty circles and solid 
line). The numbers of E. coli decreased significantly on visit 2 while the numbers of 
Enterobacteriaceae (Klebsiella, Enterobacter, Citrobacter and Pseudomonas species), 
enterococci and B. fragilis were moderately suppressed. E. coli and Enterobactericeae 
were normalized in the fecal microflora 2 weeks after end of treatment. Enterococci and 
B. fragilis were normalized in the fecal microflora 1 week after end of treatment. One 
non-toxigenic C. difficile strain was detected from volunteer number 7 on visit 3 in the 
immediate release treatment group.  
 
4.2.4 Colonization with new resistant strains 
In the extended release ciprofloxacin group, one volunteer became colonized with 
resistant E. coli strains. In addition, six volunteers were colonized with resistant E. 
faecium and three volunteers were colonized with resistant E. faecalis strains. In the 
immediate release ciprofloxacin group, three volunteers were colonized with resistant 
E. faecium and three volunteers were colonized with E. faecalis. 
 
4.2.5 Adverse effects and tolerability 
No adverse effects or serious adverse effects were reported during the study. Both 
extended and immediate release formulation ciprofloxacin were safe and well tolerated 
in both study groups. 
 
4.3 EFFECT OF TELAVANCIN ON HUMAN INTESTINAL MICROFLORA 
(PAPER III) 
4.3.1 Telavancin pharmacokinetics in plasma and urine 
All the volunteers (6 males and 7 females) finished the study successfully. In plasma 
(Figure 4) evaluation of Cmin values indicated that steady state was achieved by Day 4 
without any further increases. The plasma concentration of telavancin increased until 
the end of infusion (1 h). The mean (± standard deviation) Cmax obtained amounted to 
80.3 ± 9.9 μg/ml. After infusion was stopped, the concentration initially dropped 
rapidly (distribution phase), but eventually declined with a mean t1/2 of 6.51 ± 0.93 h 
(Fig. 4). Mean CL and Vdss were low and amounted to 1.26 ± 0.15 L/h and 11.6 ± 1.4 
L/h, respectively. For Vz, a slightly higher mean value of 11.8 ± 1.5 L/h was obtained. 
The mean area under the concentration–time curve over a dosing interval (AUCtau) 
amounted to 545 ± 65 h μg/ml. Telavancin was extensively excreted in the urine, with a 
mean CLR of 0.812 ± 0.165 L/h. A mean amount of 436 ± 75 mg telavancin was 
recovered from urine, corresponding to 64.4% (11.6%) of the administered dose. 
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Figure 4. Mean steady-state plasma concentration versus time profile of telavancin after 
the last dose (Day 7). 
 
4.3.2 Telavancin concentrations in feces 
No measurable concentrations (mg/kg) of telavancin were found in the fecal samples 
on Days −1 (pre-dose), 2, 5, 7, 9, 14 and 21. 
 
4.3.3 Effect of telavancin on the aerobic intestinal microflora 
The effect of telavancin on the aerobic intestinal microflora is shown in Figure 5. The 
mean numbers of enterococci were within the normal variations (1 log CFU/g feces). 
No significant effects (>2 log CFU/g feces) on the mean numbers of E. coli and other 
Enterobacteriaceae species were observed during or after the administration of 
telavancin. The mean numbers of C. albicans in the intestinal microflora was not 
changed within the study period. Changes in the aerobic intestinal microflora were not 
significant. 
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Figure 5. Effect of telavancin administration on the aerobic intestinal microflora of 13 
healthy volunteers. Solid line represents mean value of logarithmic number of 
microorganisms/g feces. 
 
4.3.4 Effect of telavancin on the anaerobic intestinal microflora 
Figure 6 shows the effect of telavancin on the anaerobic intestinal microflora. No 
significant effects (>2 log CFU/g feces) on the mean numbers of lactobacilli, 
bifidobacteria and Bacteroides spp. were observed before, during or after the 
administration of telavancin. Mean numbers of clostridia species decreased by 1.5 log 
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CFU/g feces from Day 1 to Day 7, with recovery of baseline counts on Day 21. No C. 
difficile strains or toxins were detected. The changes in the anaerobic intestinal 
microflora were not significant. 
 
 
Figure 6. Effect of telavancin administration on the anaerobic intestinal microflora of 
13 healthy volunteers. Solid line represents mean value of logarithmic number of 
bacteria/g feces. 
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4.3.5 Telavancin susceptibility tests 
Telavancin MICs were evaluated for the Gram-positive isolates. No new colonizing 
aerobic or anaerobic Gram-positive bacteria resistant to telavancin (MIC ≥ 2 mg/l) were 
found. 
 
4.3.6 Safety data 
The relevant treatment-emergent adverse events (TEAEs) were considered and 
recorded by the investigator. Taste abnormality was reported by eight volunteers. 
Headache, nausea and urine abnormality were reported by three volunteers, sleepiness 
was reported by one volunteer, mild gastrointestinal disorders were reported by eight 
volunteers. During the study no volunteers died and there were no serious TEAEs. 
None of the adverse events resulted in a volunteer's discontinuation of the study. 
Results from the clinical laboratory were unremarkable and did not identify any 
increased risk of renal dysfunction following multiple doses of telavancin.  
 
4.4 ECOLOGICAL IMPACT OF DOXYCYCLINE AT LOW DOSE ON 
NORMAL OROPHARYNGEAL AND INTESTINAL MICROFLORA 
(PAPER IV) 
4.4.1 Eligible and non-eligible volunteers 
In the doxycycline group, one volunteer was excluded from the study because of an 
episode of vestibular neuritis. Another volunteer in the doxycycline group was 
excluded due to a flexor tendon rupture in the right hand after an accident with a 
kitchen knife and subsequent antibiotic prophylaxis (cloxacillin 2 g orally, one dose) 
given to cover surgical suturing of the flexor tendon. However, all the samples from 
this volunteer were analyzed. In the placebo group, one volunteer with a UTI received 
pivmecillinam 200 mg orally b.i.d. for 7 days and provided only two samples. Another 
volunteer had received ciprofloxacin 500 mg orally b.i.d. for 7 days for the treatment of 
a UTI during the visits at Weeks 16 and 20. These volunteers were excluded. 
 
4.4.2 Doxycycline concentrations in plasma, saliva and feces 
Plasma doxycycline concentrations in the volunteers receiving doxycycline are shown 
in Table 2. The concentrations in samples taken after dosing were as follows: baseline 
visit, 0.20–0.61 mg/l (mean 0.47 mg/l); 4-week visit, 0.30–1.04 mg/l (mean 0.68 mg/l); 
8-week visit, 0.43–1.49 mg/l (mean 0.72 mg/l); and 16-week visit, 0.32–1.12 mg/l 
(mean 0.75 mg/l). No doxycycline was detected in plasma at the 20-week visit. No 
doxycycline was detected in the plasma samples in the placebo group at the five visits.  
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Volunteer 
No. 
Concentration (mg/l) 
Baseline
1 
Week 4 Week 8 Week 16 Week 20 
      
5 0.33
 
0.64 0.57 0.96 ND
2 
6 0.45 0.60 0.52 0.53 ND 
8 0.58 0.65 0.68 1.03 ND 
9 0.57 1.04 0.69 1.04 ND 
11 0.42 0.80 0.70 0.35 ND 
12 0.61 0.72 1.38 0.84 ND 
14 0.20 1.04 0.86 -
4 
ND 
18 0.49 0.70 0.66 1.12 ND 
19 0.51 1.03 1.49 0.94 ND 
22 0.37 0.41 0.43 0.63 ND 
23 0.61 0.30 0.80 0.84 ND 
25 0.57 0.64 0.68 0.85 -
3 
31 0.38 0.69 0.50 0.32 ND 
32 0.47 0.43 0.47 0.56 ND 
35 0.50 0.68 0.68 0.45 ND 
36 0.39 0.70 0.66 0.71 ND 
      
Range 0.20-0.61 0.30-1.04 0.43-1.49 0.32-1.12 ND 
Mean 0.47 0.68 0.72 0.75 ND 
Median 0.49 0.68 0.68 0.84 ND 
SD 0.11 0.21 0.30 0.26 ND 
1
Baseline plasma sample taken 2 h after administration of doxycycline; 
2
ND – Not 
Detected; 
3
- Sample missing; 
4
- Not reported 
 
Table 2. Doxycycline plasma concentrations in 16 volunteers receiving 40 mg 
doxycycline capsule once daily for 16 weeks. 
 
 
No doxycycline was detected in the saliva samples at the five visits in the volunteers 
receiving doxycycline and the volunteers receiving placebo. Fecal doxycycline 
concentrations in the volunteers receiving doxycycline are presented in Table 3. The 
concentrations were as follows: baseline visit, 0 mg/kg; 4-week visit, 0–3.71 mg/kg 
(mean 0.95 mg/kg); 8-week visit, 0–1.85 mg/kg (mean 0.51 mg/kg); 16-week visit, 0–
4.10 mg/kg (mean 0.98 mg/kg); and 20-week visit, 0 mg/kg. No doxycycline was 
detected in the fecal samples in the placebo group during the five visits. 
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Volunteer 
No. 
Concentration (mg/kg) 
Baseline Week 4 Week 8 Week 16 Week 20 
      
5 ND
1 
1.16 0.73 0.40 ND 
6 ND ND 1.00 2.39 ND 
8 ND 0.41 0.35 ND ND 
9 ND 0.86 0.33 0.46 ND 
11 ND 0.75 ND 0.25 ND 
12 ND 0.65 ND ND ND 
14 ND ND 1.25 1.87 ND 
18 ND 0.41 0.46 1.03 ND 
19 ND 2.67 ND 4.10 ND 
22 ND 0.82 0.29 0.26 ND 
23 ND 3.71 0.59 0.89 ND 
25 ND 2.22 1.85 1.86 -
2 
31 ND 0.38 ND 0.29 ND 
32 ND ND 0.28 0.38 ND 
35 ND 0.30 0.42 0.64 ND 
36 ND 0.92 0.54 0.93 ND 
      
Range ND 0 - 3.71 0 - 1.85 0 - 4.10 ND 
Mean ND 0.95 0.51 0.98 ND 
Median ND 0.70 0.39 0.55 ND 
SD ND 1.05 0.51 1.09 ND 
1
ND – Not Detected; 2- Sample missing 
 
Table 3. Doxycycline fecal concentrations in 16 volunteers receiving 40 mg 
doxycycline capsule once daily for 16 weeks. 
 
4.4.3 Effect of doxycycline on the oropharyngeal microflora 
The effect of doxycycline on the aerobic oropharyngeal microflora is shown in Figure 7 
There were no significant changes (>2 log CFU/ml) in the numbers of Streptococcus 
salivarius, Streptococcus mitis, Neisseria, micrococci, Candida spp. or other 
microorganisms during the 16 weeks of doxycycline administration. The aerobic 
microflora was normal at Week 20. 
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Figure 7. Effect of administration of doxycycline (— ● —) or placebo (– – ○ – –) on 
the aerobic oropharyngeal microflora. Log numbers of microorganisms are represented 
as symbols, with the mean value as lines. 
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Figure 8. Effect of administration of doxycycline (— ● —) or placebo (– – ○ – –) on 
the anaerobic oropharyngeal microflora. Log numbers of microorganisms are 
represented as symbols, with the mean value as lines. 
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Figure 8 shows the effect of doxycycline on the anaerobic oropharyngeal microflora. 
There were no significant changes (>2 log CFU/ml) in the numbers of anaerobic cocci, 
actinomyces, lactobacilli, leptotrichia and prevotella during the 16-week administration 
of doxycycline. Fusobacteria decreased at Week 8. 
 
4.4.4 Effect of placebo on the oropharyngeal microflora 
The effect of placebo on the aerobic oropharyngeal microflora is presented in Figure 7. 
The numbers of S. salivarius, S. mitis, Neisseria, micrococci, Candida spp. and other 
microorganisms were not significantly changed (>2 log CFU/ml) during the 20-week 
period. 
The effect of placebo on the anaerobic oropharyngeal microflora is shown in Figure 8. 
The numbers of anaerobic cocci, actinomyces, lactobacilli and prevotella were not 
significantly changed (>2 log CFU/ml) during the 20-week period. Fusobacteria 
decreased at Week 8 and leptotrichia decreased at Week 20. 
 
4.4.5 Effect of doxycycline on the intestinal microflora 
Figure 9 presents the effect of doxycycline on the aerobic intestinal microflora. There 
were changes (2 log CFU/g) in the numbers of enterococci and E. coli during the 16 
weeks of doxycycline administration. Other microorganisms such as other 
enterobacteria, Candida spp. and other microorganisms were not affected. The aerobic 
microflora was normal at Week 20. 
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Figure 9. Effect of administration of doxycycline (— ●–—) or placebo (– – ○ – –) on 
the aerobic intestinal microflora. Log numbers of microorganisms are represented as 
symbols, with the mean value as lines. 
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Figure 10 presents the effect of doxycycline on the anaerobic intestinal microflora. 
There were no significant changes (>2 log CFU/g) in the numbers of lactobacilli, 
bifidobacteria, clostridia and Bacteroides during the 16 weeks of doxycycline 
administration. No C. difficile strains were isolated. At Week 20 the anaerobic 
microflora was normal. 
 
 
 
Figure 10. Effect of administration of doxycycline (— ● —) or placebo (– – ○ – –) on 
the anaerobic intestinal microflora. Log numbers of microorganisms are represented as 
symbols, with the mean value as lines. 
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4.4.6 Effect of placebo on the intestinal microflora 
Figure 9 shows the effect of placebo on the aerobic intestinal microflora. The number 
of enterococci was changed (>2 log CFU/g) during the initial 4-week period. There was 
a minor change in the number of E. coli during the 20-week period. The numbers of 
other enterobacteria and Candida spp. were not changed. The numbers of other 
microorganisms were significantly increased during the initial 8-week period. 
Figure 10 shows the effect of placebo on the anaerobic intestinal microflora. The 
numbers of lactobacilli, bifidobacteria, clostridia and Bacteroides were not significantly 
changed (>2 log CFU/g) during the 20-week period. No C. difficile strains were 
isolated. 
 
4.4.7 New colonizing doxycycline-resistant microorganisms in the 
oropharyngeal and intestinal microflora 
New colonizing doxycycline-resistant microorganisms are defined as microorganisms 
growing at a doxycycline MIC ≥ 4 mg/l that were not present at the baseline visit. In 
the oropharyngeal microflora, resistant Gram-positive cocci were isolated in the 
doxycycline group but not in the placebo group. There were no other marked 
differences in the isolation frequency between the two groups. In the anaerobic 
oropharyngeal microflora, significantly more doxycycline-resistant Gram-positive rods, 
veillonella and prevotella were found in the doxycycline group than in the placebo 
group (data not shown). 
In the intestinal microflora, E. faecalis, E. faecium and Gram-positive rods were found 
significantly more in the doxycycline group than in the placebo group. In the anaerobic 
intestinal microflora, more doxycycline-resistant anaerobic cocci, bifidobacteria and 
Gram-positive rods were isolated in the doxycycline group than in the placebo group 
(data not shown). 
 
4.4.8 Safety and tolerability 
One hundred AEs were reported in 33 volunteers, of which the majority were mild and 
transient. No serious AEs were observed and four AEs were classified as related to 
treatment. These involved two episodes of diarrhea in one volunteer and one episode of 
genital candida infection in another volunteer; both of the volunteers were in the 
placebo group. In the doxycycline group in one volunteer flushing was reported. The 
most common AEs were headache (38 episodes in 16 volunteers), and nasopharyngitis 
(28 episodes in 19 volunteers). Less common AEs that were pyrexia (3 episodes in 3 
volunteers, with 2 subjects in the doxycycline group), oropharyngeal pain (3 episodes 
in 2 volunteers, 1 in each treatment group), diarrhea (3 episodes in 2 volunteers, 1 in 
each treatment group), nausea (2 episodes in 2 volunteers, both in the placebo group) 
and UTI (2 episodes in 2 volunteers, both in the placebo group). 
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5 DISCUSSION 
 
Antibiotics are one of the fundamental revolutions of modern medicine [22, 79, 80, 
187]. Antibiotic consumption not only fortifies modern medicine, but has taken 
enormous modifications to human health [22, 72-74, 79, 80, 187]. The developing 
problem of antibiotic resistance is a severe warning to comprehensive public health [22, 
72-74, 79, 80, 187]. The growing occurrence of resistant and multi-resistant bacterial 
strains worldwide is placing a major problem on healthcare systems and civilization 
[22, 72-74, 79, 80, 187]. “Antimicrobial resistance: no action today and no cure 
tomorrow” was the theme of World Health Day 2011 [188]. The condition is provoked 
by a significant weakening in research and development into antibacterial agents [22, 
187]. 
The extensive use of antibiotics both in humans and animals has caused the 
development of many resistant bacteria and subsequently limited their use in therapy 
[79, 80, 187, 189]  Resistance is undoubtedly not limited to one antibiotic and has been 
reported amongst most classes of antibacterials [79, 80, 187, 189]. Administration of 
antibacterial agents can cause disturbances in the ecological balance between the host 
and microorganisms [6, 7]. These changes are dependent on the spectrum of activity, 
dose, route of administration, pharmacokinetic and pharmacodynamic properties and in 
vivo inactivation of the agent [6, 7]. Secretion of an agent by intestinal mucosa or bile 
may have an impact on the intestinal microflora leading to antibiotic resistance [6, 7]. 
 
5.1 CEFTOBIPROLE (PAPER I) 
For the treatment of complicated skin infections and pneumonia, ceftobiprole is a 
promising antimicrobial agent [190]. The effect of ceftobiprole on the normal intestinal 
microflora has not been studied earlier. No fecal concentration of ceftobiprole was 
found and the minor effect on the intestinal microflora is thus explained by these 
results. Ceftobiprole is mainly eliminated by renal excretion [105]. No new colonizing 
ceftobiprole-resistant aerobic and anaerobic bacteria in the normal intestinal flora were 
recovered, probably due to less selective pressure for the emergence of colonization by 
resistant microorganisms. CDI is an adverse event mainly associated with antibiotic 
treatment and prophylaxis [11]. Broad-spectrum antibiotics such as cephalosporins, 
fluoroquinolones and amoxicillin are most often involved in causing the CDI [36, 123]. 
In the paper I, no clinical C. difficile infection was observed, probably due to lack of 
biological activity of ceftobiprole in the intestine. Ceftobiprole is reported to be well 
tolerated with good safety, which was also observed in paper I [191]. Based on the 
findings in paper I, ceftobiprole has a favorable ecological profile. However, when 
ceftobiprole is used in hospitalized patients with serious infections and pre-existing C. 
difficile strains, the risk of development of CDI should be monitored. 
 
5.2 CIPROFLOXACIN (PAPER II) 
Ciprofloxacin is a widely used fluroquinolone for the treatment of UTIs with high 
bactericidal activity against uropathogens and has a well-established clinical efficacy 
[192]. The impact of ciprofloxacin on the human intestinal microflora has been studied 
before and measurable concentration of ciprofloxacin in feces had been detected [193-
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197]. The anaeerobic and aerobic bacteria in the fecal flora were suppressed markedly 
during the prophylactic period as well as throughout treatment period [6, 193]. The 
intestinal microflora was almost normal within 2 weeks after the treatment by 
ciprofloxacin [6]. The concentrations of ciprofloxacin in the intestinal mucosa and 
feces were in excess of the MICs for most of the anaerobic and aerobic bacteria [6, 
193]. In paper II, the effects of the two formulations of ciprofloxacin on the normal 
microflora were compared. Measurable concentrations of ciprofloxacin in feces were 
detected in both groups. The aerobic fecal flora was suppressed during the treatment in 
both study groups and the microflora was normal 2 weeks after the end of the 
treatment. Both formulations had minor effects on the intestinal normal anaerobic 
microflora. No toxigenic C. difficile strains or toxins were detected in this study. 
Compared with other fluoroquinolones, ciprofloxacin has lower impact on the normal 
microflora and in causing CDI [36, 123, 198]. Based on the results from paper II, on the 
microbiological data on the intestinal microflora as well as on the bioassays for 
antibiotic concentrations in the fecal samples, no major differences could be observed 
between the new extended release formulation and the immediate release formulation 
ciprofloxacin. 
 
5.3 TELAVANCIN (PAPER III) 
The impact of telavancin on the normal intestinal microflora has not been studied 
previously. Telavancin is a semisynthetic derivative of vancomycin and is 
recommended for the treatment of adult patients with complicated skin and skin-
structure infections caused by Gram-positive bacteria [140, 141, 199, 200]. Most often 
described adverse reactions have been reported to be mild and reversible, with taste 
disturbance, headache, nausea, vomiting and procedural site pain [130]. Telavancin was 
well tolerated in the study III and is excreted primarily by renal elimination, with 60–
70% of the dose excreted unchanged in the urine and <1% in the feces. Renal 
dysfunction has been found more frequently with telavancin than vancomycin [130, 
199, 201]. Prolongation of corrected QT (QTc) interval has been reported for 
telavancin, but no clinically significant ECG changes have been seen [140]. Owing to 
its t1/2 of ca. 6.5 h with low intersubject variability, a steady state of telavancin was 
already achieved by Day 4 in all volunteers. Telavancin showed low variability in Cmax 
and AUCtau between volunteers, resulting in a consistent and predictable exposure. In 
paper III, the main route for elimination was via renal excretion of unchanged 
telavancin, which accounted for 64.4% of its elimination. No fecal concentration of 
telavancin was found, which probably explains the lack of an effect on the intestinal 
microflora. No new colonizing telavancin-resistant anaerobic and aerobic Gram-
positive bacteria in the normal flora were recovered, probably due to less selective 
pressure for the emergence of colonization by resistant microorganisms. No toxigenic 
C. difficile strains were detected in the subjects during or after treatment with 
telavancin. Based on the results from paper III, the microbiological data on the 
intestinal microflora as well as the results of the bioassays for antibiotic concentrations 
in fecal samples, telavancin has a favorable ecological profile. 
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5.4 DOXYCYCLINE (PAPER IV) 
Extensive use of tetracyclines both in humans and animals has caused the development 
of many resistant bacteria and subsequently limited the use of tetracyclines in the 
treatment of infections [151, 153, 154]. Tetracyclines have many other interesting 
properties not related to their antibiotic activity [144, 156, 157]. Tetracyclines have 
independent anti-inflammatory effects at subantimicrobial doses [144, 156, 157]. A 
large amount of literature has provided evidence for the anti-inflammatory properties of 
tetracyclines as well as in the management of acne and rosacea [158, 159, 161-163, 
202]. The traditional tetracycline dose has an effect on antibiotic susceptibility and 
resistance development on the host microflora [169, 170]. Subantimicrobial 
doxycycline, which has the benefit of fewer AEs compared with higher doses, has 
raised questions about potential changes in antibiotic susceptibility of the host 
microflora, an event known to occur with higher-dose doxycycline [176, 177]. Many 
studies have shown that a long-term subantimicrobial doxycycline dose does not 
contribute to changes in antibiotic susceptibility and resistance of the host microflora 
[176, 177]. In the study IV, it was found that a subantimicrobial doxycycline dose (40 
mg) had a minor ecological effect on the oropharyngeal and intestinal microflora. The 
oropharyngeal and intestinal microflora in the doxycycline group had more resistant 
Gram-positive cocci, Gram-positive rods, veillonella, prevotella, E. faecalis and E. 
faecium than the placebo group. The clinical significance of this finding is not apparent 
and more studies will be needed with a lower dose of doxycycline (20 mg) in order to 
maintain the anti-inflammatory effects without any ecological impact on the normal 
microflora. 
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6 CONCLUSION 
This thesis shows that intravenous administration of antibiotics (ceftobiprole and 
telavancin) has less impact on the intestinal microflora if excreted through urine. As a 
consequence, there is less disruption of the normal microflora by the antibiotics and 
low risk to develop CDI. The antibiotic (ciprofloxacin) that had an impact on the 
intestinal microflora regardless of the formulations of dose release, has potential risk to 
cause CDI. The sub-antimicrobial dose of antibiotics (doxycycline) has effects on the 
normal microflora in relation to placebo. The sub-antimicrobial dose of antibiotics has 
a selective pressure on microflora and it may cause a development of resistance or to 
increase the frequency of the resistance among commensals. 
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7 FUTURE PERSPECTIVES OF THE NORMAL FLORA 
STUDY 
For the treatment of infections by antibiotics, the importance is to eradicate the 
pathogen as quickly as possible with minimal adverse effects on the host and minimal 
disruption of the normal microflora. This may decrease the frequency of resistance 
development against antibiotics. Using the best methods to predict the effects of 
antibiotics on the dominant microflora of healthy humans it is possible to predict the 
impact of antibiotics by studying the dominant microflora. Antibiotics have effects on 
the susceptible microflora directly and on the non-susceptible microflora indirectly. 
There are scopes to develop suitable methods to predict the impacts of antibiotics on 
the minor microflora and to discover their relation with the dominant microflora as well 
as the immunological consequences and health for the host. Studying the microbiome 
using advanced and specific molecular methods can predict the impact on the 
uncultivable normal microflora. However, the molecular technology does not reflect on 
the phenotypic properties of the normal microflora. Conventional studies are very 
important to identify new resistance patterns. By studying the resistance mechanisms, it 
will be possible to design and invent new drugs that will have less influence on the 
normal microflora. Additionally, it is important to gain knowledge on the mechanisms 
or pathways by which the microorganisms become resistant to certain antibiotics and 
by reversing or inhibiting the pathways or mechanisms the drug can be still active. The 
molecular studies are using different classification methods to identify normal 
microflora and are also avoiding minor microflora to present their results. Recent 
comparison studies show that molecular studies are not superior to culture based 
studies. Molecular studies are at this moment still very expensive. Therefore, there is 
still a need for further development of the molecular methods to be comparable with the 
culture-based methods. A multi-disciplinary approach is needed since the whole 
bacterial community plays a role in antibiotic resistance. Future research is required to 
discover additional ways how bacteria communicate with each other, with the 
environment and with other microorganisms. We do not have suitable methods to know 
any particular antibiotic concentration at the active site of the microorganisms. We 
have methods to measure the surrogate concentrations of antibiotics by using blood or 
epithelial lining fluids. A multi-disciplinary approach is therefore needed to solve the 
problem. It will eventually help to use appropriate dosages of antibiotics that may show 
less impact on the normal microflora, new ways to combat the emergence of antibiotic 
resistance and decrease the risk of resistance development. 
 
We are conducting a collaborative study with six European countries to understand 
how the administration of standard doses of antibiotics affects the normal microflora 
during one year. Both molecular and conventional methods are the basis of the study. It 
will give new insights into limiting resistance development and transmission of 
antibiotic-resistant bacterial strains. The genetic basis of drug resistance is studied 
together with the persistence and mode of transmission of antibiotic-resistant strains, 
biological cost to the microorganism, resistant phenotype and ecological impact. 
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